Clinical Outcome With Correlation to Disseminated Tumor Cell (DTC) Status After DTC-Guided Secondary Adjuvant Treatment With Docetaxel in Early Breast Cancer

Naume, Bjørn; Synnestvedt, Marit; Falk, Ragnhild Sørum; Wiedswang, Gro; Weyde, Kjetil; Risberg, Terje; Kersten, Christian; Mjaaland, Ingvil; Vindi, Lise; Sommer, H; Sætersdal, Anna Barbro; Rypdal, Maria Christine; Schirmer, Cecilie Bendigtsen; Wist, Erik; Borgen, Elin

doi:10.1200/jco.2014.56.9327

Cited by 71 publications

(49 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Docetaxel is a hemisynthetic compound derived from 10-deacetylbaccatin III (a non-cytotoxic precursor extracted from the needles of the European yew tree, Taxus baccata L (Naume et al, 2014), one of the members of the taxoid family similar to paclitaxel, and can promote microtubule assembly and inhibit depolymerization to free tubulin, which results in the blockage of the cells in the M phase of the cell cycle (Bissery et al, 1995). Cyclophosphamide (CTX) is a nitrogen mustard alkylating agent synthesized in the 1940s, which is broad-spectrum and cell cycle-nonspecific.…”

Section: Discussionmentioning

confidence: 99%

Protective Effect of Astragalus polysaccharides on Liver Injury Induced by Several Different Chemotherapeutics in Mice

Liu

Gao²,

Li³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Protective Effect of Astragalus polysaccharides on Liver Injury Induced by Several Different Chemotherapeutics in Mice

Liu

Gao²,

Li³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…DTC status can be used to identify high‐risk patients after chemotherapy and guide treatment decisions. However, DTC status after surgery was not associated with overall survival (Table ) …”

Section: Dtc In Bone Marrow May Be a Prognostic Biomarker For Relapsementioning

confidence: 99%

Disseminated tumour cells in bone marrow are the source of cancer relapse after therapy

Sai

Xiang

2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

Accumulating evidence indicates that cancer cells spread much earlier than was previously believed. Recent technological advances have greatly improved the detection methods of circulating tumour cells (CTCs), suggesting that the dissemination of cancer cells into the circulation occurs randomly. Most CTCs die in circulation as a result of shear stress and/or anoikis. However, the persistence of disseminated tumour cells (DTCs) in the bone marrow is the result of interaction of DTCs with bone marrow microenvironment. DTCs in the bone marrow undergo successive clonal expansions and a parallel progression that leads to new variants. Compared to the CTCs, DTCs in the bone marrow have a unique signature, which displayed dormant, mesenchymal phenotype and osteoblast‐like or osteoclast‐like phenotype. The persistence of DTCs in the bone marrow is always related to minimal residual diseases (MRDs). This review outlines the difference between CTCs and DTCs in the bone marrow and describes how this difference affects the clinical values of CTCs and DTCs, such as metastasis and recurrence. We suggest that DTCs remaining in the bone marrow after therapy can be used as a superior marker in comparison with CTCs to define patients with an unfavourable prognosis and may therefore be a potential prognostic factor and therapeutic target for cancer therapy.

show abstract

“…A promising implementation of liquid biopsies would be to guide adjuvant treatment selection and monitor its therapeutic effect; such preliminary results have been generated through the assessment of disseminated tumour cells (DTCs) in the bone marrow of patients with early breast cancer [58]. …”

Section: The Promise Of Liquid Biopsiesmentioning

confidence: 99%

The past and future of breast cancer treatment—from the papyrus to individualised treatment approaches

Ades

Tryfonidis

Zardavas

2017

ecancer

View full text Add to dashboard Cite

Cancer is one of the oldest diseases ever described, since ancient Egypt there have always been attempts to treat and cure this illness. The growing body of knowledge about breast cancer biology and improvements in surgical and medical treatments has been built over time with contributions from many talented and enthusiastic physicians and researchers. Medical advances have changed the approach from a previously incurable condition, into a surgical disease. Further improvements in cancer biology have allowed the development of systemic treatments, hormonal therapies, and targeted drugs. The description of the molecular intrinsic subtypes of breast cancer clarified the understanding of breast cancer as a group of heterogeneous diseases, associated with different clinical outcomes, and therapeutic opportunities. This paper reviews how breast cancer treatment has improved since the earliest descriptions, in ancient times, and how future approaches, such as gene signatures, molecular profiling, and liquid biopsies, aim to further develop individualised treatments and improve treatment outcomes.

show abstract

Clinical Outcome With Correlation to Disseminated Tumor Cell (DTC) Status After DTC-Guided Secondary Adjuvant Treatment With Docetaxel in Early Breast Cancer

Abstract: DTC status identifies high-risk patients after FEC chemotherapy, and DTC monitoring status after secondary treatment with docetaxel correlated strongly with survival. This emphasizes the potential for DTC analysis as a surrogate marker for adjuvant treatment effect in breast cancer.

Cited by 71 publications

References 77 publications

Protective Effect of Astragalus polysaccharides on Liver Injury Induced by Several Different Chemotherapeutics in Mice

Protective Effect of Astragalus polysaccharides on Liver Injury Induced by Several Different Chemotherapeutics in Mice

Disseminated tumour cells in bone marrow are the source of cancer relapse after therapy

The past and future of breast cancer treatment—from the papyrus to individualised treatment approaches

Contact Info

Product

Resources

About